Lv61
2430 积分 2024-08-15 加入
Drug evaluation: maribavir as a cytomegalovirus antiviral agent
26天前
已完结
The emergence of letermovir and maribavir drug-resistant mutations: from clinical trials to real-world studies
26天前
已完结
Antibiotic therapy for severe bacterial infections
1个月前
已完结
Susceptibility patterns of amphotericin B, itraconazole, posaconazole, voriconazole and caspofungin for isolates causing invasive mould infections from the SENTRY Antifungal Surveillance Program (2018–2021) and application of single‐site epidemiological cutoff values to evaluate amphotericin B activity
1个月前
已完结
Pharmacokinetics of Maribavir, a Novel Oral Anticytomegalovirus Agent, in Subjects With Varying Degrees of Renal Impairment
2个月前
已完结
2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists
3个月前
已完结
Real-world safety of maribavir: a retrospective study based on signal detection in the FDA adverse event reporting system
3个月前
已完结
Real‐World Experience With Maribavir for Treatment of Refractory or Resistant Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients
3个月前
已完结
新型抗巨细胞病毒药物—马立巴韦
3个月前
已完结
KDIGO Clinical Practice Guidelines for Acute Kidney Injury
4个月前
已完结
皖公网安备34019202002308
